-transparent.png){kind=logo}
An attempt was made to increase the in vivo immunosuppressive powers of antilymphocyte globulin (ALG) by conjugating it with malphalan (MEL), an alkylating agent, via an inert intermediate carrier (polyglutamic acid). Careful controls to distinguish between increased activity attributable to the conjugate per se, as opposed to synergy between the components of the complex, were included. Conjugation did not destroy the alkylating properties of the drug nor the cytotoxic activity of the antibody. The effect of MEL-ALG complexes on skin allograft survival in both inbred and outbred strains were appraised. In neither system did the immunosuppressive powers of the conjugate exceed those of ALG alone, regardless of the dose used. We conclude that alkylating drugs are not suitable for this particular purpose.
L Brent, and
T Horsburgh, and
G Rowland, and
P Wood
January 1969,
Lancet (London, England),
L Brent, and
T Horsburgh, and
G Rowland, and
P Wood
September 1972,
Transplantation,
L Brent, and
T Horsburgh, and
G Rowland, and
P Wood
November 1980,
Vnitrni lekarstvi,
L Brent, and
T Horsburgh, and
G Rowland, and
P Wood
March 1980,
Clinical immunology and immunopathology,
L Brent, and
T Horsburgh, and
G Rowland, and
P Wood
January 1969,
Surgical forum,
L Brent, and
T Horsburgh, and
G Rowland, and
P Wood
December 1971,
Transplantation,
L Brent, and
T Horsburgh, and
G Rowland, and
P Wood
March 1973,
Transplantation proceedings,
L Brent, and
T Horsburgh, and
G Rowland, and
P Wood
December 1976,
Canadian Medical Association journal,
L Brent, and
T Horsburgh, and
G Rowland, and
P Wood
March 1977,
Transplantation proceedings,
L Brent, and
T Horsburgh, and
G Rowland, and
P Wood
February 1970,
Transplantation,
